N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.

N-(3-fluoro-4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazine-1-yl)butyl)arylcarboxamides were prepared and evaluated for binding and function at dopamine D3 receptors (D3Rs) and dopamine D2 receptors (D2Rs). In this series, we discovered some of the most D3R selective compounds reported to date (e.g., 8d and 8j, >1000-fold D3R-selective over D2R). In addition, chimeric receptor studies further identified the second extracellular (E2) loop as an important contributor to D3R binding selectivity. Further, compounds lacking the carbonyl group in the amide linker were synthesized, and while these amine-linked analogues bound with similar affinities to the amides at D2R, this modification dramatically reduced binding affinities at D3R by >100-fold (e.g., D3R K(i) for 15b = 393 vs for 8j = 2.6 nM), resulting in compounds with significantly reduced D3R selectivity. This study supports a pivotal role for the D3R E2 loop and the carbonyl group in the 4-phenylpiperazine class of compounds and further reveals a point of separation between structure-activity relationships at D3R and D2R.

[1]  R. Spealman,et al.  Dopamine D3 and D2 Receptor Mechanisms in the Abuse-Related Behavioral Effects of Cocaine: Studies with Preferential Antagonists in Squirrel Monkeys , 2010, Journal of Pharmacology and Experimental Therapeutics.

[2]  R. Mach,et al.  Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands , 2006 .

[3]  Robert R Luedtke,et al.  Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR. , 2007, Bioorganic & medicinal chemistry letters.

[4]  Erin E. Carlson,et al.  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. , 2005, Journal of medicinal chemistry.

[5]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[6]  J. Ballesteros,et al.  The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.

[7]  Robert H Mach,et al.  Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. , 2005, Bioorganic & medicinal chemistry.

[8]  R. Mach,et al.  Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats , 2009, Neuropharmacology.

[9]  Peter Gmeiner,et al.  The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. , 2006, Pharmacology & therapeutics.

[10]  A. Newman,et al.  Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders , 2010, Annals of the New York Academy of Sciences.

[11]  A. Newman,et al.  Dopamine D3 Receptors Mediate the Discriminative Stimulus Effects of Quinpirole in Free-Feeding Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[12]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[13]  J. Hagan,et al.  1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists , 2007 .

[14]  Francesca Zazzeroni,et al.  The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors , 2010, Molecular Pharmacology.

[15]  J. Palacios,et al.  Visualization of dopamine D1, D2 and D3 receptor mRNA's in human and rat brain , 1992, Neurochemistry International.

[16]  M. Reith,et al.  Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action. , 2008, Journal of medicinal chemistry.

[17]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[18]  M. Millan,et al.  Dopamine D3 receptor antagonists as therapeutic agents. , 2005, Drug discovery today.

[19]  Lei Shi,et al.  The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Susanta K. Sarkar,et al.  Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists , 2010, Psychopharmacology.

[21]  A. Capelli,et al.  1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists. , 2010, Journal of medicinal chemistry.

[22]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[23]  R. Mach,et al.  Characterization of 125I‐IABN, a novel azabicyclononane benzamide selective for D2‐like dopamine receptors , 2000, Synapse.

[24]  K. Neve,et al.  Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors , 2006, Molecular Pharmacology.

[25]  Bernardo L. Sabatini,et al.  Competitive regulation of synaptic Ca influx by D2 dopamine and A2A adenosine receptors , 2010, Nature Neuroscience.

[26]  R. Mach,et al.  Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. , 2010, Bioorganic & medicinal chemistry.

[27]  G. Koob,et al.  PRECLINICAL STUDY: FULL ARTICLE: The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended‐access , 2010, Addiction biology.

[28]  Harald Hübner,et al.  Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding. , 2009, Journal of medicinal chemistry.

[29]  A. Newman,et al.  Dopamine Agonist-Induced Yawning in Rats: A Dopamine D3 Receptor-Mediated Behavior , 2005, Journal of Pharmacology and Experimental Therapeutics.

[30]  Ji-Kyung Choi,et al.  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. , 2007, Journal of medicinal chemistry.

[31]  Robert R Luedtke,et al.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. , 2009, Journal of medicinal chemistry.